Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danirixin dose-ranging placebo-controlled study in adults with COPD
NL-OMON45435Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of danirixin in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by GSK. Primary endpoints: Change from baseline in respiratory symptoms measured by the E-RS:COPD daily diary and Adverse events. Started Sep 2017; status: active, not recruiting.
02
Drugs
danirixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON45435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45435.